NEW YORK, March 13, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS
Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE:
GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Perrigo Company Analyst Notes
On February 28, 2014, Perrigo
Company (Perrigo) reported its acquisition of a basket of
value-brand OTC products sold in Australia and New
Zealand from Aspen Global Inc. for $51 million in cash. According to the Company,
the acquired products include Herron® range of analgesics, vitamins
and supplements, and are expected to generate at least $20 million in annual revenue. Perrigo's
Chairman, President and CEO, Joseph C.
Papa said, "The acquisition of OTC products in Australia enhances our position by broadening
our product offering and increasing our relevance with the mass
retail customers. This deal furthers our strategy to expand our
Consumer Healthcare portfolio internationally, while making quality
products more affordable for consumers and customers around the
world." The full analyst notes on Perrigo Company are available to
download free of charge at:
http://www.AnalystsReview.com/03132014/PRGO/report.pdf
--
Zoetis Inc Analyst Notes
On March 4, 2014, Zoetis Inc
(Zoetis) announced that it has appointed Dr. Wille M. Reed to its Board of Directors.
According to the Company, in his new role, Dr. Reed will serve on
the Corporate Governance Committee of the Board. Dr. Reed serves as
the Dean of the College of Veterinary Medicine at Purdue University, and has more than 30 years of
experience in animal health and veterinary medicine. The Company
stated that as a recognized expert in avian pathology, diagnostic
medicine and infectious diseases, Dr. Reed brings perspectives on
veterinary medicine that will be crucial as Zoetis continues to
enhance its reputation as a world leader in animal health. The
Company believes that Dr. Reed will add valuable scientific
expertise to the Zoetis Board, as well as a unique understanding of
the needs of Zoetis customers and the animals that depend on the
company's medicines and vaccines. The full analyst notes on Zoetis
Inc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ZTS/report.pdf
--
ISIS Pharmaceuticals, Inc. Analyst
Notes
On March 6, 2014, ISIS
Pharmaceuticals, Inc. (ISIS) announced its participation at the
upcoming Barclays Global Healthcare Conference. The Company
informed that the conference will take place on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami,
Florida. According to the Company, interested parties can
view the live webcast of the presentation on the "Investors &
Media" section of ISIS' website. The full analyst notes on ISIS
Pharmaceuticals, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03132014/ISIS/report.pdf
--
GlaxoSmithKline plc Analyst Notes
On March 9, 2014, GlaxoSmithKline
plc (GSK) announced that the Company has successfully increased its
stake in its publicly-listed pharmaceuticals subsidiary in
India, GlaxoSmithKline
Pharmaceuticals Limited, from 50.7% to 75% following the voluntary
Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd.
David Redfern, Chief Strategy
Officer, GSK, said, "We are very pleased with the outcome of this
transaction, which further increases our exposure to a
strategically important market. It is a significant vote of
confidence in the future growth prospects of our Pharmaceuticals
business in India and underlines
GSK's long-standing commitment to the country." The full analyst
notes on GlaxoSmithKline plc are available to download free of
charge at:
http://www.AnalystsReview.com/03132014/GSK/report.pdf
--
AstraZeneca plc Analyst Notes
On March 3, 2014, AstraZeneca plc
(AstraZeneca) announced that its BYDUREON® Pen (exenatide
extended-release for injectable suspension) 2 mg as an adjunct to
diet and exercise to improve glycaemic control in adults with type
2 diabetes, has been approved by the U.S. Food and Drug
Administration (FDA). According to the Company, BYDUREON is
the first and only once-weekly medicine for adults with type 2
diabetes, and is a pre-filled, single-use pen injector, eliminating
the need for the patient to transfer the medication between a vial
and syringe during the self-injection process. AstraZeneca informed
that the BYDUREON Pen contains the same formulation and dose as the
original BYDUREON single-dose tray, providing the same continuous
release of exenatide. The full analyst notes on AstraZeneca plc are
available to download free of charge at:
http://www.AnalystsReview.com/03132014/AZN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review